COMUNICAZIONI EX ART. 41, COMMA 2 LETTERA C) RE 11971/99 - DIFFUSI PER CONTO DI BENIAMINO GAVIO E MARCELLO GAVIO
V. ALL
SIGNED AN INVESTMENT AGREEMENT WITH U.S. INVESTOR GLOBAL CORPORATE FINANCE
Trieste, 31 July 2025 – Ulisse Biomed S.p.A. (“UBM” or the “Company” or the “Group”), an Italian healthcare biotech company operating in the fields of diagnostics, theranostics and therapeutics, announces that today has signed an investment agreement (the “Agreement”) with the U.S. based entities Global Corporate Finance (the “Investor”) and Sterling Atlantic, LLC (“SAP”).
SOTTOSCRITTO UN ACCORDO DI INVESTIMENTO CON L’INVESTITORE STATUNITENSE GLOBAL CORPORATE FINANCE
Trieste, 31 luglio 2025 – Ulisse Biomed S.p.A.
CS Ricavi consolidati H1 2025
IL CONSIGLIO D’AMMINISTRAZIONE PRENDE VISIONE DEI DATI CONSOLIDATI AL 30 GIUGNO 2025 RICAVI VENDITE CONSOLIDATI PARI AD EURO C. 14 MILIONI (15,3 MILIONI AL 30.06.24) RICAVI SEMI, END-MARKET INDUSTRIAL & AI, IN CRESCITA DEL 28% RISPETTO AL 30.06.24